SABRA REPORTS THIRD QUARTER 2026 RESULTS; UPDATES 2026 GUIDANCE
TUSTIN, CA, November 2, 2026 — Sabra Health Care REIT, Inc. (“Sabra,” the “Company” or “we”) (Nasdaq: SBRA) today announced its results of operations for the third quarter of 2026.
• Results per diluted common share for the third quarter of 2026 were as follows:
• On a year-over-year basis, same property Senior Housing Operating Portfolio (“SHOP”) Cash NOI increased 14.6% for the third quarter of 2026.
• As previously announced, Sabra closed on the acquisition of seven SHOP communities for an aggregate price of $222.8 million in the third quarter with an estimated yield of 7.7%.
• Investments closed year to date total $747.2 million, with an estimated yield of 8.0%.
• Sabra has been awarded an additional $425 million of investments, of which about $385 million is SHOP, $25 million is skilled nursing and $15 million is preferred equity, with an estimated yield of 7.0%. These investments are currently in the Letter of Intent or later stage, and Sabra expects to fund these investments, if consummated, with available liquidity, including proceeds from outstanding forward sales agreements under its at-the-market equity offering program (“ATM program”).
• Sabra’s closed and awarded SHOP investments are expected to generate unlevered IRRs in the low-teens, providing for strong current income and the potential for outsized future earnings growth.
• On October 1, 2026, Sabra completed the previously announced transition of 26 properties formerly leased to Avamere, with 22 properties being transitioned to subsidiaries of Cascadia Healthcare and four properties being transitioned to subsidiaries of the Ensign Group. As a result of this transition, effective October 1, 2026, annualized cash rent for these properties increased to $53 million from $48 million.
• During the third quarter of 2026, Sabra utilized the forward feature of the ATM program to allow for the sale of up to 0.1 million shares of the Company’s common stock at an initial weighted average price of $19.94 per share. As of September 30, 2026, 15.0 million shares remained outstanding under forward sale agreements at a weighted average price of $19.53 per share, net of commissions.
• On November 2, 2026, Sabra’s Board of Directors declared a quarterly cash dividend of $0.30 per share of common stock. The dividend will be paid on November 30, 2026, to common stockholders of record as of the close of business on November 13, 2026.
Sabra is updating its 2026 earnings guidance ranges as follows (attributable to Sabra Health Care REIT, Inc., per diluted common share):
• low-single-digit Cash NOI growth for the triple-net portfolio at the midpoint, ignoring the impact of acquisitions, dispositions and completed or planned tenant transitions;
• general and administrative expenses at the midpoint of $63 million, which includes nearly $15 million of stock-based compensation expense;
• weighted average share counts of 260 million and 261 million for Normalized FFO and Normalized AFFO, respectively;
• only investments, dispositions and capital markets activity already completed as of the date of this release.
The foregoing guidance ranges reflect management’s view of current and future market conditions. There can be no assurance that the Company’s actual results will not differ materially from the estimates set forth above. Except as otherwise required by law, the Company assumes no, and hereby disclaims any, obligation to update any of the foregoing guidance ranges as a result of new information or new or future developments.
Commenting on the third quarter’s results, Rick Matros, CEO and Chair, said, “Sabra delivered another strong quarter. Same store SHOP Cash NOI margins and REVPOR growth are among the best in the space accompanied by solid occupancy and cash NOI growth. Investment activity continues to be robust, with $425 million currently awarded and more expected to come before year end. We expect our SHOP concentration to be around 40% on a run rate basis by year end 2026 and 50% by the end of 2027. We continue to evaluate our skilled nursing portfolio for optimization opportunities along the lines of our July announcement.
Our triple-net skilled nursing and senior housing portfolios again showed increased rent coverage. Leverage ticked down, and we increased our guidance at the midpoint. We do not foresee any barriers that would slow down our current momentum and the shift in our portfolio mix to be more heavily weighted towards SHOP, which will continue to be supported by an exceptionally strong triple-net skilled nursing portfolio.”
As of September 30, 2026, we had approximately $1.2 billion of liquidity, consisting of unrestricted cash and cash equivalents of $36.2 million, available borrowings under our revolving credit facility of $873.5 million and $292.5 million related to shares outstanding under forward sale agreements under the ATM program. As of September 30, 2026, we also had $332.7 million available under our ATM program.
A conference call with a simultaneous webcast to discuss the 2026 third quarter results will be held on Tuesday, November 3, 2026, at 10:00 am Pacific Time. The webcast URL is https://events.q4inc.com/attendee/325673757. The dial-in number for U.S. participants is (833) 461-5787. For participants outside the U.S., the dial-in number is (585) 542-9983. The conference ID number is 325673757. A digital replay of the call will be available on the Company’s website at www.sabrahealth.com. The Company’s supplemental information package for the third quarter will also be available on the Company’s website in the “Investors” section.
As of September 30, 2026, Sabra’s investment portfolio included 364 real estate properties held for investment (consisting of (i) 207 skilled nursing/transitional care facilities, (ii) 32 senior housing communities (“senior housing - leased”), (iii) 24 specialty hospitals and other facilities and (iv) 101 senior housing communities operated by third-party property managers pursuant to property management agreements (“senior housing operating portfolio” or “SHOP”)), 11 investments in loans receivable (consisting of two mortgage loans and nine other loans), four preferred equity investments and two investments in unconsolidated joint ventures. As of September 30, 2026, Sabra’s real estate properties held for investment included 37,513 beds/units, spread across the United States and Canada.
This release contains “forward-looking” statements as defined in the Private Securities Litigation Reform Act of 1995. Any statements that do not relate to historical or current facts or matters are forward-looking statements. These statements may be identified, without limitation, by the use of “expects,” “believes,” “intends,” “should” or comparable terms or the negative thereof. Examples of forward-looking statements include all statements regarding our other expectations regarding our future financial position (including our earnings guidance for 2026, as well as the assumptions set forth therein); our expectations regarding our results of operations, cash flows, liquidity, business strategy, growth opportunities, potential investments and dispositions; our expectations regarding our investment activity; and our plans and objectives for future operations.
Our actual results may differ materially from those projected or contemplated by our forward-looking statements as a result of various factors, including, among others, the following: the ability to reach a definitive agreement for awarded investments and our ability to close such acquisitions on the expected terms or at all; increases in market interest rates and inflation; pandemics or epidemics, and the related impact on our tenants, borrowers and SHOP communities; operational risks with respect to our SHOP communities; increased labor costs and labor shortages; competitive conditions in our industry; the loss of key management personnel; uninsured or underinsured losses affecting our properties; potential impairment charges and adjustments related to the accounting of our assets; risks associated with our investment in our unconsolidated joint ventures; catastrophic weather and other natural or man- made disasters, the effects of climate change on our properties and a failure to implement sustainable and energy-efficient measures; increased operating costs and competition for our tenants, borrowers and SHOP communities; increased healthcare regulation and enforcement; our tenants’ dependency on reimbursement from governmental and other third-party payor programs; the effect of our tenants, operators or borrowers declaring bankruptcy or becoming insolvent; our ability to find replacement tenants and the impact of unforeseen costs in acquiring new properties; the impact of litigation and rising insurance costs on the business of our tenants; the impact of required regulatory approvals of transfers of healthcare properties; environmental compliance costs and liabilities associated with real estate properties we own; our tenants’, borrowers’ or operators’ failure to adhere to applicable privacy and data security laws; a material breach of our or our tenants’, borrowers’ or operators’ information technology; our concentration in the healthcare property sector, particularly in skilled nursing/transitional care facilities and senior housing communities, which makes our profitability more vulnerable to a downturn in a specific sector than if we were investing in multiple industries; the significant amount of and our ability to service our indebtedness; covenants in our debt agreements that may restrict our ability to pay dividends, make investments, incur additional indebtedness and refinance indebtedness on favorable terms; adverse changes in our credit ratings; our ability to make dividend distributions at expected levels; our ability to raise capital through equity and debt financings; changes and uncertainty in macroeconomic conditions and disruptions in the financial markets; risks associated with our ownership of
property outside the U.S., including currency fluctuations; the relatively illiquid nature of real estate investments; our ability to maintain our status as a real estate investment trust (“REIT”) under the federal tax laws; compliance with REIT requirements and certain tax and tax regulatory matters related to our status as a REIT; changes in tax laws and regulations affecting REITs; the ownership limits and takeover defenses in our governing documents and under Maryland law, which may restrict change of control or business combination opportunities; and the exclusive forum provisions in our bylaws.
Additional information concerning risks and uncertainties that could affect our business can be found in our filings with the Securities and Exchange Commission (the “SEC”), including in Part I, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2025. We do not intend, and we undertake no obligation, to update any forward-looking information to reflect events or circumstances after the date of this release or to reflect the occurrence of unanticipated events, unless required by law to do so.
This release includes information regarding certain of our tenants that lease properties from us and our borrowers, most of which are not subject to SEC reporting requirements. The information related to our tenants and borrowers that is provided in this release has been provided by, or derived from information provided by, such tenants and borrowers. We have not independently verified this information. We have no reason to believe that such information is inaccurate in any material respect. We are providing this data for informational purposes only.
This release includes the following financial measures defined as non-GAAP financial measures by the SEC: Net Debt to Adjusted EBITDA, funds from operations (“FFO”), Normalized FFO, Adjusted FFO (“AFFO”), Normalized AFFO, FFO per diluted common share, Normalized FFO per diluted common share, AFFO per diluted common share, Normalized AFFO per diluted common share, net operating income (“NOI”) and Cash NOI. These measures may be different than non-GAAP financial measures used by other companies, and the presentation of these measures is not intended to be considered in isolation or as a substitute for financial information prepared and presented in accordance with U.S. generally accepted accounting principles. An explanation of these non-GAAP financial measures is included under “Reporting Definitions” in this release, and reconciliations of these non-GAAP financial measures to the GAAP financial measures we consider most comparable are included on the Investors section of our website at https://ir.sabrahealth.com/investors/financials/quarterly- results.
(1) See the following page for additional details regarding rental and related revenues.
September 30, 2026 December 31, 2025 ────────────────────────────────────────────────────────────────────────────── Assets Real estate investments, net of accumulated depreciation of $1,322,145 $ 4,925,213 $ 4,686,377 and $1,224,663 as of September 30, 2026 and December 31, 2025, respectively Loans receivable and other investments, 120,295 434,100 net Investment in unconsolidated joint 114,631 118,166 ventures Cash and cash equivalents 36,240 71,537 Restricted cash 6,842 6,603 Lease intangible assets, 87,180 65,321 net Accounts receivable, prepaid expenses 139,551 111,292 and other assets, net Total assets $ 5,429,952 $ 5,493,396 Liabilities Secured debt, net $ 41,706 $ 43,275 Revolving credit facility 126,503 217,584 Term loans, net 1,030,224 1,032,311 Senior unsecured notes, net 1,237,543 1,235,726 Accounts payable and 135,005 119,329 accrued liabilities Lease intangible 17,696 21,383 liabilities, net Total liabilities 2,588,677 2,669,608 Equity Preferred stock, $0.01 par value; 10,000,000 shares authorized, zero — — shares issued and outstanding as of September 30, 2026 and December 31, 2025 Common stock, $0.01 par value; 500,000,000 shares authorized, 261,961,461 and 251,697,456 shares 2,620 2,517 issued and outstanding as of September 30, 2026 and December 31, 2025, respectively Additional paid-in capital 5,014,619 4,836,270 Cumulative distributions in excess of -2,200,671 -2,013,375 net income Accumulated other comprehensive income 23,083 -3,571 (loss) Total Sabra Health Care REIT, Inc. 2,839,651 2,821,841 stockholders’ equity Noncontrolling interests 1,624 1,947 Total equity 2,841,275 2,823,788 Total liabilities and $ 5,429,952 $ 5,493,396 equity
Nine Months Ended Cash flows from September 30, operating activities: 2026 2025 ────────────────────────────────────────────────────────────────────────────── Net income $ 44,122 $ 128,363 Adjustments to reconcile net income to net cash provided by operating activities: Depreciation and 174,289 135,591 amortization Non-cash rental and -1,005 820 related revenues Non-cash interest 7,110 5,608 expense Stock-based 11,109 8,290 compensation expense Loss on extinguishment — 1,154 of debt Provision for (recovery of) loan 104,600 -640 losses and other reserves Net gain on sales of -29,652 -5,544 real estate Impairment of real 440 6,674 estate Income from unconsolidated joint -6,366 -2,276 ventures Distributions of earnings from 5,814 5,917 unconsolidated joint ventures Other non-cash items — -17,183 Changes in operating assets and liabilities: Accounts receivable, prepaid expenses -16,449 -9,129 and other assets, net Accounts payable and 19,140 3,541 accrued liabilities Net cash provided by operating 313,152 261,186 activities Cash flows from investing activities: Acquisition of real estate and lease -516,346 -301,563 intangibles Origination and fundings of loans -994 -5,710 receivable Origination and fundings of preferred -2,612 -9 equity investments Additions to real -41,058 -24,183 estate Escrow deposits for potential -60 -500 investments Repayments of loans 210,743 15,442 receivable Repayments of preferred equity 2,897 1,977 investments Investment in unconsolidated joint — -1,241 ventures Net proceeds from the sales of real 156,860 43,087 estate Proceeds from net — 4,462 investment hedges Insurance proceeds 136 1,267 Distributions in excess of earnings from — 5,557 unconsolidated joint ventures Net cash used in -190,434 -261,414 investing activities Cash flows from financing activities: Net (repayments of) borrowings from -90,200 174,805 revolving credit facility Principal payments on senior unsecured — -500,000 notes Proceeds from term — 500,000 loans Principal payments on -1,604 -1,562 secured debt Payments of deferred -111 -4,405 financing costs Payments related to extinguishment of — -2,884 debt Contributions from noncontrolling 2 2,040 interests Distributions to noncontrolling -162 — interests Payment of contingent -1,178 — consideration Issuance of common 163,691 188,350 stock, net Dividends paid on -227,953 -214,692 common stock Net cash (used in) provided by financing -157,515 141,652 activities Net (decrease) increase in cash, cash -34,797 141,424 equivalents and restricted cash Effect of foreign currency translation on cash, cash -261 -245 equivalents and restricted cash Cash, cash equivalents and restricted 78,140 66,339 cash, beginning of period Cash, cash equivalents and restricted $ 43,082 $ 207,518 cash, end of period Supplemental disclosure of cash flow information: Interest paid $ 69,552 $ 72,820 Supplemental disclosure of non-cash investing activities: Decrease in loans receivable and other investments due to $ 16,600 $ — acquisition of real estate
(1) Other normalizing items for FFO and AFFO for the three and nine months ended September 30, 2026 include a $10.2 million deferred rent payment related to a triple-net lease. Other normalizing items for FFO for the nine months ended September 30, 2025 include a $17.2 million gain reclassified from other comprehensive loss related to six previously terminated interest rate swaps as the related forecasted transactions were determined to be probable not to occur and $3.4 million of transition expenses related to the transition of SHOP communities to new operators. Other normalizing items for AFFO for the nine months ended September 30, 2025 include $3.4 million of transition expenses related to the transition of SHOP communities to new operators. In addition, other normalizing items for FFO and AFFO include triple-net operating expenses, net of recoveries.
(2) Other adjustments for the nine months ended September 30, 2025 include a $17.2 million gain reclassified from other comprehensive loss related to six previously terminated interest rate swaps as the related forecasted transactions were determined to be probable not to occur.
Adjusted EBITDA is calculated as earnings before interest, taxes, depreciation and amortization (“EBITDA”) excluding the impact of merger-related costs, stock- based compensation expense under the Company’s long-term equity award program and loan loss reserves. Adjusted EBITDA is an important non-GAAP supplemental measure of operating performance.
The Company believes that net income as defined by GAAP is the most appropriate earnings measure. The Company considers Cash NOI an important supplemental measure because it allows investors, analysts and its management to evaluate the operating performance of its investments. The Company defines Cash NOI as total revenues less operating expenses and non-cash revenues and expenses. Cash NOI excludes all other financial statement amounts included in net income and is presented at Sabra’s pro rata share.
Earnings before interest, taxes, depreciation, amortization, rent and management fees (“EBITDARM”) for a particular facility accruing to the operator/tenant of the property (not the Company), for the period presented. The Company uses EBITDARM in determining EBITDARM Coverage. EBITDARM has limitations as an analytical tool. EBITDARM does not reflect historical cash expenditures or future cash requirements for facility capital expenditures or contractual commitments. In addition, EBITDARM does not represent a property’s net income or cash flows from operations and should not be considered an alternative to those indicators. The Company utilizes EBITDARM to evaluate the core operations of the properties by eliminating management fees, which may vary by operator/tenant and operating structure, and as a supplemental measure of the ability of the Company’s operators/tenants and relevant guarantors to generate sufficient liquidity to meet related obligations to the Company.
Represents the ratio of EBITDARM to cash rent for owned facilities (excluding SHOP communities) for the period presented. EBITDARM Coverage is a supplemental measure of a property’s ability to generate cash flows for the operator/tenant (not the Company) to meet the operator’s/tenant’s related cash rent and other obligations to the Company. However, its usefulness is limited by, among other things, the same factors that limit the usefulness of EBITDARM. EBITDARM Coverage includes only Stabilized Facilities and excludes facilities for which data is not available or meaningful.
The Company believes that net income as defined by GAAP is the most appropriate earnings measure. The Company also believes that funds from operations, or FFO, as defined in accordance with the definition used by the National Association of Real Estate Investment Trusts (“Nareit”), and adjusted funds from operations, or AFFO (and related per share amounts) are important non-GAAP supplemental measures of the Company’s operating performance. Because the historical cost accounting convention used for real estate assets requires straight-line depreciation (except on land), such accounting presentation implies that the value of real estate assets diminishes predictably over time. However, since real estate values have historically risen or fallen with market and other conditions, presentations of operating results for a real estate investment trust that uses historical cost accounting for depreciation could be less informative. Thus, Nareit created FFO as a supplemental measure of operating performance for real estate investment trusts that excludes historical cost depreciation and amortization, among other items, from net income, as defined by GAAP. FFO is defined as net income, computed in accordance with GAAP, excluding gains or losses from real estate dispositions and the Company’s share of gains or losses from real estate dispositions related to its unconsolidated joint ventures, plus real estate depreciation and amortization, net of amounts related to noncontrolling interests, plus the Company’s share of depreciation and amortization related to its unconsolidated joint ventures, and real estate impairment charges of both consolidated and unconsolidated entities when the impairment is directly attributable to decreases in the value of depreciable real estate held by the entity. AFFO is defined as FFO excluding stock-based compensation expense, non-cash rental and related revenues, non-cash interest income, non-cash interest expense, non-cash portion of loss on extinguishment of debt, provision for (recovery of) loan losses and other reserves, non-cash lease termination income and deferred income taxes, as well as other non-cash revenue and expense items (including noncapitalizable acquisition costs, transaction costs related to operator transitions and organizational or other restructuring activities, gain/loss on derivative instruments, and non-cash revenue and expense amounts related to noncontrolling interests) and the Company’s share of non-cash adjustments related to its unconsolidated joint ventures. The Company believes that the use of FFO and AFFO (and the related per share amounts), combined with the required GAAP presentations, improves the understanding of the Company’s
operating results among investors and makes comparisons of operating results among real estate investment trusts more meaningful. The Company considers FFO and AFFO to be useful measures for reviewing comparative operating and financial performance because, by excluding the applicable items listed above, FFO and AFFO can help investors compare the operating performance of the Company between periods or as compared to other companies. While FFO and AFFO are relevant and widely used measures of operating performance of real estate investment trusts, they do not represent cash flows from operations or net income as defined by GAAP and should not be considered an alternative to those measures in evaluating the Company’s liquidity or operating performance. FFO and AFFO also do not consider the costs associated with capital expenditures related to the Company’s real estate assets nor do they purport to be indicative of cash available to fund the Company’s future cash requirements. Further, the Company’s computation of FFO and AFFO may not be comparable to FFO and AFFO reported by other real estate investment trusts that do not define FFO in accordance with the current Nareit definition or that interpret the current Nareit definition or define AFFO differently than the Company does.
Represents the carrying amount of real estate assets after adding back accumulated depreciation and amortization and excludes net intangible assets and liabilities.
The principal balances of the Company’s revolving credit facility, term loans, senior unsecured notes and secured indebtedness as reported in the Company’s consolidated financial statements, net of cash and cash equivalents as reported in the Company’s consolidated financial statements.
The Company believes that net income as defined by GAAP is the most appropriate earnings measure. The Company considers Net Debt to Adjusted EBITDA an important supplemental measure because it provides investors, analysts and its management with a meaningful indicator of the Company’s financial leverage and its capacity to service and repay debt from operating cash flows. Net Debt to Adjusted EBITDA is calculated as Net Debt divided by Annualized Adjusted EBITDA, which is Adjusted EBITDA, as adjusted for annualizing adjustments that give effect to the acquisitions and dispositions completed during the respective period as though such acquisitions and dispositions were completed as of the beginning of the period presented.
The Company believes that net income as defined by GAAP is the most appropriate earnings measure. The Company considers NOI an important supplemental measure because it allows investors, analysts and its management to evaluate the operating performance of its investments. The Company defines NOI as total revenues less operating expenses. NOI excludes all other financial statement amounts included in net income.
Normalized FFO and Normalized AFFO represent FFO and AFFO, respectively, adjusted for certain income and expense items that the Company does not believe are indicative of its ongoing operating results. The Company considers Normalized FFO and Normalized AFFO to be useful measures to evaluate the Company’s operating results excluding these income and expense items to help investors compare the operating performance of the Company between periods or as compared to other companies. Normalized FFO and Normalized AFFO do not represent cash flows from operations or net income as defined by GAAP and should not be considered an alternative to those measures in evaluating the Company’s liquidity or operating performance. Normalized FFO and Normalized AFFO also do not consider the costs associated with capital expenditures related to the Company’s real estate assets nor do they purport to be indicative of cash available to fund the Company’s future cash requirements. Further, the Company’s computation of Normalized FFO and Normalized AFFO may not be comparable to Normalized FFO and Normalized AFFO reported by other real estate investment trusts that do not define FFO in accordance with the current Nareit definition or that interpret the current Nareit definition or define FFO and AFFO or Normalized FFO and Normalized AFFO differently than the Company does.
Senior Housing communities include independent living, assisted living, continuing care retirement and memory care communities.
Senior Housing communities operated by third-party property managers pursuant to property management agreements.
Skilled Nursing/Transitional Care facilities include skilled nursing, transitional care and multi-license designation facilities.
Includes psychiatric, acute care, long-term acute care and rehabilitation hospitals, facilities that provide residential services, which may include assistance with activities of daily living, and other facilities not classified as Skilled Nursing/Transitional Care or Senior Housing.
At the time of acquisition, the Company classifies each facility as either stabilized or non-stabilized. In addition, the Company may classify a facility as non-stabilized after acquisition. Circumstances that could result in a facility being classified as non-stabilized include newly completed developments, facilities undergoing major renovations or additions, facilities being repositioned or transitioned to new operators and significant transitions within the tenants’ business model. Such facilities are typically reclassified to stabilized upon the earlier of maintaining consistent performance or 24 months after the date of classification as non-stabilized. Stabilized Facilities generally exclude (i) facilities held for sale, (ii) strategic disposition candidates, (iii) facilities being transitioned to a new operator, (iv) facilities being transitioned from being leased by the Company to being operated by the Company and (v) leased facilities acquired during the three months preceding the period presented.
Reconciliations, definitions and important discussions regarding the usefulness and limitations of the Non-GAAP Financial Measures used in this supplement can be found at https://ir.sabrahealth.com/investors/financials/quarterly-results.
Full text with the tables
Exhibit 99.1
FOR IMMEDIATE RELEASE
SABRA REPORTS THIRD QUARTER 2026 RESULTS; UPDATES 2026 GUIDANCE
TUSTIN, CA, November 2, 2026 — Sabra Health Care REIT, Inc. (“Sabra,” the
“Company” or “we”) (Nasdaq: SBRA) today announced its results of operations for
the third quarter of 2026.
THIRD QUARTER 2026 RESULTS
• Results per diluted common share for the third quarter of 2026 were as
follows:
• Net Income: $0.11
• FFO: $0.40
• Normalized FFO: $0.39
• AFFO: $0.45
• Normalized AFFO: $0.41
• EBITDARM Coverage Summary:
• Skilled Nursing/Transitional Care: 2.52x
• Senior Housing - Leased: 1.58x
• Specialty Hospitals and Other: 3.91x
• On a year-over-year basis, same property Senior Housing Operating Portfolio
(“SHOP”) Cash NOI increased 14.6% for the third quarter of 2026.
INVESTMENTS AND PORTFOLIO ACTIVITY
• As previously announced, Sabra closed on the acquisition of seven SHOP
communities for an aggregate price of $222.8 million in the third quarter with
an estimated yield of 7.7%.
• Investments closed year to date total $747.2 million, with an estimated yield
of 8.0%.
• Sabra has been awarded an additional $425 million of investments, of which
about $385 million is SHOP, $25 million is skilled nursing and $15 million is
preferred equity, with an estimated yield of 7.0%. These investments are
currently in the Letter of Intent or later stage, and Sabra expects to fund
these investments, if consummated, with available liquidity, including proceeds
from outstanding forward sales agreements under its at-the-market equity
offering program (“ATM program”).
• Sabra’s closed and awarded SHOP investments are expected to generate unlevered
IRRs in the low-teens, providing for strong current income and the potential for
outsized future earnings growth.
• On October 1, 2026, Sabra completed the previously announced transition of 26
properties formerly leased to Avamere, with 22 properties being transitioned to
subsidiaries of Cascadia Healthcare and four properties being transitioned to
subsidiaries of the Ensign Group. As a result of this transition, effective
October 1, 2026, annualized cash rent for these properties increased to $53
million from $48 million.
1
OTHER RECENT EVENTS
• During the third quarter of 2026, Sabra utilized the forward feature of the
ATM program to allow for the sale of up to 0.1 million shares of the Company’s
common stock at an initial weighted average price of $19.94 per share. As of
September 30, 2026, 15.0 million shares remained outstanding under forward sale
agreements at a weighted average price of $19.53 per share, net of commissions.
• As of September 30, 2026, Net Debt to Adjusted EBITDA was 4.54x.
• On November 2, 2026, Sabra’s Board of Directors declared a quarterly cash
dividend of $0.30 per share of common stock. The dividend will be paid on
November 30, 2026, to common stockholders of record as of the close of business
on November 13, 2026.
UPDATED FULL-YEAR 2026 GUIDANCE
Sabra is updating its 2026 earnings guidance ranges as follows (attributable to
Sabra Health Care REIT, Inc., per diluted common share):
• Net Income: $0.265 - $0.275
• FFO: $1.145 - $1.155
• Normalized FFO: $1.540 - $1.550
• AFFO: $1.625 - $1.635
• Normalized AFFO: $1.600 - $1.610
Earnings guidance above assumes:
• low-single-digit Cash NOI growth for the triple-net portfolio at the midpoint,
ignoring the impact of acquisitions, dispositions and completed or planned
tenant transitions;
• average full-year Cash NOI growth for same store SHOP in the mid-teens;
• general and administrative expenses at the midpoint of $63 million, which
includes nearly $15 million of stock-based compensation expense;
• cash interest expense of $106 million at the midpoint;
• weighted average share counts of 260 million and 261 million for Normalized
FFO and Normalized AFFO, respectively;
• only investments, dispositions and capital markets activity already completed
as of the date of this release.
The foregoing guidance ranges reflect management’s view of current and future
market conditions. There can be no assurance that the Company’s actual results
will not differ materially from the estimates set forth above. Except as
otherwise required by law, the Company assumes no, and hereby disclaims any,
obligation to update any of the foregoing guidance ranges as a result of new
information or new or future developments.
Commenting on the third quarter’s results, Rick Matros, CEO and Chair, said,
“Sabra delivered another strong quarter. Same store SHOP Cash NOI margins and
REVPOR growth are among the best in the space accompanied by solid occupancy and
cash NOI growth. Investment activity continues to be robust, with $425 million
currently awarded and more expected to come before year end. We expect our SHOP
concentration to be around 40% on a run rate basis by year end 2026 and 50% by
the end of 2027. We continue to evaluate our skilled nursing portfolio for
optimization opportunities along the lines of our July announcement.
Our triple-net skilled nursing and senior housing portfolios again showed
increased rent coverage. Leverage ticked down, and we increased our guidance at
the midpoint. We do not foresee any barriers that would slow down our current
momentum and the shift in our portfolio mix to be more heavily weighted towards
SHOP, which will continue to be supported by an exceptionally strong triple-net
skilled nursing portfolio.”
2
LIQUIDITY
As of September 30, 2026, we had approximately $1.2 billion of liquidity,
consisting of unrestricted cash and cash equivalents of $36.2 million, available
borrowings under our revolving credit facility of $873.5 million and $292.5
million related to shares outstanding under forward sale agreements under the
ATM program. As of September 30, 2026, we also had $332.7 million available
under our ATM program.
CONFERENCE CALL AND COMPANY INFORMATION
A conference call with a simultaneous webcast to discuss the 2026 third quarter
results will be held on Tuesday, November 3, 2026, at 10:00 am Pacific Time. The
webcast URL is https://events.q4inc.com/attendee/325673757. The dial-in number
for U.S. participants is (833) 461-5787. For participants outside the U.S., the
dial-in number is (585) 542-9983. The conference ID number is 325673757. A
digital replay of the call will be available on the Company’s website at
www.sabrahealth.com. The Company’s supplemental information package for the
third quarter will also be available on the Company’s website in the “Investors”
section.
ABOUT SABRA
As of September 30, 2026, Sabra’s investment portfolio included 364 real estate
properties held for investment (consisting of (i) 207 skilled
nursing/transitional care facilities, (ii) 32 senior housing communities
(“senior housing - leased”), (iii) 24 specialty hospitals and other facilities
and (iv) 101 senior housing communities operated by third-party property
managers pursuant to property management agreements (“senior housing operating
portfolio” or “SHOP”)), 11 investments in loans receivable (consisting of two
mortgage loans and nine other loans), four preferred equity investments and two
investments in unconsolidated joint ventures. As of September 30, 2026, Sabra’s
real estate properties held for investment included 37,513 beds/units, spread
across the United States and Canada.
FORWARD-LOOKING STATEMENTS SAFE HARBOR
This release contains “forward-looking” statements as defined in the Private
Securities Litigation Reform Act of 1995. Any statements that do not relate to
historical or current facts or matters are forward-looking statements. These
statements may be identified, without limitation, by the use of “expects,”
“believes,” “intends,” “should” or comparable terms or the negative thereof.
Examples of forward-looking statements include all statements regarding our
other expectations regarding our future financial position (including our
earnings guidance for 2026, as well as the assumptions set forth therein); our
expectations regarding our results of operations, cash flows, liquidity,
business strategy, growth opportunities, potential investments and dispositions;
our expectations regarding our investment activity; and our plans and objectives
for future operations.
Our actual results may differ materially from those projected or contemplated by
our forward-looking statements as a result of various factors, including, among
others, the following: the ability to reach a definitive agreement for awarded
investments and our ability to close such acquisitions on the expected terms or
at all; increases in market interest rates and inflation; pandemics or
epidemics, and the related impact on our tenants, borrowers and SHOP
communities; operational risks with respect to our SHOP communities; increased
labor costs and labor shortages; competitive conditions in our industry; the
loss of key management personnel; uninsured or underinsured losses affecting our
properties; potential impairment charges and adjustments related to the
accounting of our assets; risks associated with our investment in our
unconsolidated joint ventures; catastrophic weather and other natural or man-
made disasters, the effects of climate change on our properties and a failure to
implement sustainable and energy-efficient measures; increased operating costs
and competition for our tenants, borrowers and SHOP communities; increased
healthcare regulation and enforcement; our tenants’ dependency on reimbursement
from governmental and other third-party payor programs; the effect of our
tenants, operators or borrowers declaring bankruptcy or becoming insolvent; our
ability to find replacement tenants and the impact of unforeseen costs in
acquiring new properties; the impact of litigation and rising insurance costs on
the business of our tenants; the impact of required regulatory approvals of
transfers of healthcare properties; environmental compliance costs and
liabilities associated with real estate properties we own; our tenants’,
borrowers’ or operators’ failure to adhere to applicable privacy and data
security laws; a material breach of our or our tenants’, borrowers’ or
operators’ information technology; our concentration in the healthcare property
sector, particularly in skilled nursing/transitional care facilities and senior
housing communities, which makes our profitability more vulnerable to a downturn
in a specific sector than if we were investing in multiple industries; the
significant amount of and our ability to service our indebtedness; covenants in
our debt agreements that may restrict our ability to pay dividends, make
investments, incur additional indebtedness and refinance indebtedness on
favorable terms; adverse changes in our credit ratings; our ability to make
dividend distributions at expected levels; our ability to raise capital through
equity and debt financings; changes and uncertainty in macroeconomic conditions
and disruptions in the financial markets; risks associated with our ownership of
3
property outside the U.S., including currency fluctuations; the relatively
illiquid nature of real estate investments; our ability to maintain our status
as a real estate investment trust (“REIT”) under the federal tax laws;
compliance with REIT requirements and certain tax and tax regulatory matters
related to our status as a REIT; changes in tax laws and regulations affecting
REITs; the ownership limits and takeover defenses in our governing documents and
under Maryland law, which may restrict change of control or business combination
opportunities; and the exclusive forum provisions in our bylaws.
Additional information concerning risks and uncertainties that could affect our
business can be found in our filings with the Securities and Exchange Commission
(the “SEC”), including in Part I, Item 1A of our Annual Report on Form 10-K for
the year ended December 31, 2025. We do not intend, and we undertake no
obligation, to update any forward-looking information to reflect events or
circumstances after the date of this release or to reflect the occurrence of
unanticipated events, unless required by law to do so.
TENANT AND BORROWER INFORMATION
This release includes information regarding certain of our tenants that lease
properties from us and our borrowers, most of which are not subject to SEC
reporting requirements. The information related to our tenants and borrowers
that is provided in this release has been provided by, or derived from
information provided by, such tenants and borrowers. We have not independently
verified this information. We have no reason to believe that such information is
inaccurate in any material respect. We are providing this data for informational
purposes only.
NOTE REGARDING NON-GAAP FINANCIAL MEASURES
This release includes the following financial measures defined as non-GAAP
financial measures by the SEC: Net Debt to Adjusted EBITDA, funds from
operations (“FFO”), Normalized FFO, Adjusted FFO (“AFFO”), Normalized AFFO, FFO
per diluted common share, Normalized FFO per diluted common share, AFFO per
diluted common share, Normalized AFFO per diluted common share, net operating
income (“NOI”) and Cash NOI. These measures may be different than non-GAAP
financial measures used by other companies, and the presentation of these
measures is not intended to be considered in isolation or as a substitute for
financial information prepared and presented in accordance with U.S. generally
accepted accounting principles. An explanation of these non-GAAP financial
measures is included under “Reporting Definitions” in this release, and
reconciliations of these non-GAAP financial measures to the GAAP financial
measures we consider most comparable are included on the Investors section of
our website at https://ir.sabrahealth.com/investors/financials/quarterly-
results.
CONTACT
Investor & Media Inquiries: (888) 393-8248 or [email protected]
4
SABRA HEALTH CARE REIT, INC.
CONSOLIDATED STATEMENTS OF INCOME
(dollars in thousands, except per share data)
Three Nine
Months Months
Ended Ended
Septem… Septe…
30, 30,
Reve… 2026 2025 2026 2025
──────────────────────────────────────────────────────────────────────────────
Rent…
and $ 103,1… $ 85,354 $ 299,536 $ 281,2…
rela…
reve…
Resi…
fees 143,1… 92,017 388,651 248,4…
and
serv…
Inte…
and 3,223 12,666 18,997 33,067
other
inco…
Total 249,5… 190,037 707,184 562,7…
reve…
Expe…
Depr…
and 64,779 48,511 174,289 135,5…
amor…
Inte… 29,161 28,901 87,349 83,549
Trip…
port… 3,658 3,708 11,087 10,885
oper…
expe…
Seni…
hous…
oper… 99,302 65,946 269,787 179,8…
port…
oper…
expe…
Gene…
and 15,584 12,560 47,265 37,802
admi…
Prov…
for
(rec…
of)
loan 2,368 -240 104,600 -640
loss…
and
other
rese…
Impa…
of — 2,571 440 6,674
real
esta…
Total 214,8… 161,957 694,817 453,6…
expe…
Other
(exp…
inco…
Loss
on
exti… — -1,154 — -1,154
of
debt
Other
(exp… -250 -769 -2,988 13,978
inco…
Net
(los…
gain
on -8,065 -4,430 29,652 5,544
sales
of
real
esta…
Total
other -8,315 -6,353 26,664 18,368
(exp…
inco…
Inco…
befo…
inco…
from
unco…
joint 26,398 21,727 39,031 127,4…
vent…
and
inco…
tax
expe…
Inco…
from
unco… 2,230 1,226 6,366 2,276
joint
vent…
Inco…
tax -71 -436 -1,275 -1,346
expe…
Net 28,557 22,517 44,122 128,3…
inco…
Net
loss
attr… 50 21 163 21
to
nonc…
inte…
Net
inco…
attr…
to
Sabra $ 28,607 $ 22,538 $ 44,285 $ 128,3…
Heal…
Care
REIT,
Inc.
Net
inco…
attr…
to
Sabra
Heal…
Care
REIT,
Inc.,
per:
Basic
comm… $ 0.11 $ 0.09 $ 0.17 $ 0.54
share
Dilu…
comm… $ 0.11 $ 0.09 $ 0.17 $ 0.53
share
Weig…
aver…
numb…
of 255,6… 239,89… 253,34… 238,5…
comm…
shar…
outs…
basic
Weig…
aver…
numb…
of 259,8… 243,55… 257,18… 241,5…
comm…
shar…
outs…
dilu…
(1) See the following page for additional details regarding rental and related
revenues.
5
SABRA HEALTH CARE REIT, INC.
CONSOLIDATED STATEMENTS OF INCOME - SUPPLEMENTAL INFORMATION
(in thousands)
Three Nine
Months Months
Ended Ended
Septemb… Septemb…
2026 30, 2025 2026 30, 2025
──────────────────────────────────────────────────────────────────────────────
Cash
rental $ 93,540 $ 88,946 $ 277,383 $ 271,414
income
Deferr…
cash 10,166 — 10,166 —
rent
payment
Straig…
rental 894 1,027 2,609 3,683
income
Write-…
of
straig…
rental
income -6,200 -9,237 -4,796 -7,759
receiv…
and
lease
intang…
Above/…
market 1,058 1,058 3,192 3,256
lease
amorti…
Operat…
expense 3,720 3,560 10,982 10,620
recove…
Rental
and $ 103,178 $ 85,354 $ 299,536 $ 281,214
related
revenu…
6
SABRA HEALTH CARE REIT, INC.
CONSOLIDATED BALANCE SHEETS
(dollars in thousands, except per share data)
September 30, 2026 December 31, 2025
──────────────────────────────────────────────────────────────────────────────
Assets
Real estate investments,
net of
accumulated depreciation of
$1,322,145 $ 4,925,213 $ 4,686,377
and $1,224,663 as of
September 30, 2026
and December 31, 2025,
respectively
Loans receivable and other
investments, 120,295 434,100
net
Investment in
unconsolidated joint 114,631 118,166
ventures
Cash and cash equivalents 36,240 71,537
Restricted cash 6,842 6,603
Lease intangible assets, 87,180 65,321
net
Accounts receivable,
prepaid expenses 139,551 111,292
and other assets, net
Total assets $ 5,429,952 $ 5,493,396
Liabilities
Secured debt, net $ 41,706 $ 43,275
Revolving credit facility 126,503 217,584
Term loans, net 1,030,224 1,032,311
Senior unsecured notes, net 1,237,543 1,235,726
Accounts payable and 135,005 119,329
accrued liabilities
Lease intangible 17,696 21,383
liabilities, net
Total liabilities 2,588,677 2,669,608
Equity
Preferred stock, $0.01 par
value;
10,000,000 shares
authorized, zero — —
shares issued and
outstanding as of
September 30, 2026 and
December 31, 2025
Common stock, $0.01 par
value;
500,000,000 shares
authorized,
261,961,461 and 251,697,456
shares 2,620 2,517
issued and outstanding as
of September
30, 2026 and December 31,
2025,
respectively
Additional paid-in capital 5,014,619 4,836,270
Cumulative distributions in
excess of -2,200,671 -2,013,375
net income
Accumulated other
comprehensive income 23,083 -3,571
(loss)
Total Sabra Health Care
REIT, Inc. 2,839,651 2,821,841
stockholders’ equity
Noncontrolling interests 1,624 1,947
Total equity 2,841,275 2,823,788
Total liabilities and $ 5,429,952 $ 5,493,396
equity
7
SABRA HEALTH CARE REIT, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)
Nine Months Ended
Cash flows from September 30,
operating activities: 2026 2025
──────────────────────────────────────────────────────────────────────────────
Net income $ 44,122 $ 128,363
Adjustments to
reconcile net income
to
net cash provided by
operating
activities:
Depreciation and 174,289 135,591
amortization
Non-cash rental and -1,005 820
related revenues
Non-cash interest 7,110 5,608
expense
Stock-based 11,109 8,290
compensation expense
Loss on extinguishment — 1,154
of debt
Provision for
(recovery of) loan 104,600 -640
losses
and other reserves
Net gain on sales of -29,652 -5,544
real estate
Impairment of real 440 6,674
estate
Income from
unconsolidated joint -6,366 -2,276
ventures
Distributions of
earnings from 5,814 5,917
unconsolidated joint
ventures
Other non-cash items — -17,183
Changes in operating
assets and
liabilities:
Accounts receivable,
prepaid expenses -16,449 -9,129
and other assets, net
Accounts payable and 19,140 3,541
accrued liabilities
Net cash provided by
operating 313,152 261,186
activities
Cash flows from
investing activities:
Acquisition of real
estate and lease -516,346 -301,563
intangibles
Origination and
fundings of loans -994 -5,710
receivable
Origination and
fundings of preferred -2,612 -9
equity investments
Additions to real -41,058 -24,183
estate
Escrow deposits for
potential -60 -500
investments
Repayments of loans 210,743 15,442
receivable
Repayments of
preferred equity 2,897 1,977
investments
Investment in
unconsolidated joint — -1,241
ventures
Net proceeds from the
sales of real 156,860 43,087
estate
Proceeds from net — 4,462
investment hedges
Insurance proceeds 136 1,267
Distributions in
excess of earnings
from — 5,557
unconsolidated joint
ventures
Net cash used in -190,434 -261,414
investing activities
Cash flows from
financing activities:
Net (repayments of)
borrowings from -90,200 174,805
revolving credit
facility
Principal payments on
senior unsecured — -500,000
notes
Proceeds from term — 500,000
loans
Principal payments on -1,604 -1,562
secured debt
Payments of deferred -111 -4,405
financing costs
Payments related to
extinguishment of — -2,884
debt
Contributions from
noncontrolling 2 2,040
interests
Distributions to
noncontrolling -162 —
interests
Payment of contingent -1,178 —
consideration
Issuance of common 163,691 188,350
stock, net
Dividends paid on -227,953 -214,692
common stock
Net cash (used in)
provided by financing -157,515 141,652
activities
Net (decrease)
increase in cash, cash -34,797 141,424
equivalents and
restricted cash
Effect of foreign
currency translation
on cash, cash -261 -245
equivalents and
restricted
cash
Cash, cash equivalents
and restricted 78,140 66,339
cash, beginning of
period
Cash, cash equivalents
and restricted $ 43,082 $ 207,518
cash, end of period
Supplemental
disclosure of cash
flow
information:
Interest paid $ 69,552 $ 72,820
Supplemental
disclosure of non-cash
investing activities:
Decrease in loans
receivable and other
investments due to $ 16,600 $ —
acquisition of real
estate
8
SABRA HEALTH CARE REIT, INC.
FUNDS FROM OPERATIONS (FFO), NORMALIZED FFO,
ADJUSTED FUNDS FROM OPERATIONS (AFFO) AND NORMALIZED AFFO
(dollars in thousands, except per share data)
Three Nine
Months Months
Ended Ended
Septem… Septem…
2026 30, 2025 2026 30, 2025
──────────────────────────────────────────────────────────────────────────────
Net
income
attri…
to
Sabra $ 28,607 $ 22,538 $ 44,285 $ 128,384
Health
Care
REIT,
Inc.
Add:
Depre…
and
amort…
of 64,779 48,511 174,289 135,591
real
estate
assets
Depre…
and
amort…
of
real
estate -124 -40 -368 -40
assets
relat…
to
nonco…
inter…
Depre…
and
amort…
of
real
estate 1,474 1,722 4,478 5,945
assets
relat…
to
uncon…
joint
ventu…
Net
loss
(gain)
on 8,065 4,430 -29,652 -5,544
sales
of
real
estate
Impai…
of — 2,571 440 6,674
real
estate
FFO
attri…
to
Sabra $ 102,801 $ 79,732 $ 193,472 $ 271,010
Health
Care
REIT,
Inc.
Write…
of
strai…
rental
income 6,200 9,237 4,796 7,759
recei…
and
lease
intan…
Lease
termi…
(inco… — -1,518 2,873 -1,518
expen…
net
Loss
on
extin… — 1,154 — 1,154
of
debt
Provi…
for
(reco…
of)
loan 2,368 -240 103,327 -640
losses
and
other
reser…
Other
norma… -9,012 270 -8,410 -14,166
items…
Norma…
FFO
attri…
to
Sabra $ 102,357 $ 88,635 $ 296,058 $ 263,599
Health
Care
REIT,
Inc.
FFO
attri…
to
Sabra $ 102,801 $ 79,732 $ 193,472 $ 271,010
Health
Care
REIT,
Inc.
Stock…
compe… 3,922 2,875 11,109 8,290
expen…
Non-c…
rental
and 4,248 7,151 -1,005 820
relat…
reven…
Non-c…
inter… 2,372 2,153 7,110 5,608
expen…
Non-c…
porti…
of
loss — -1,730 — -1,730
on
extin…
of
debt
Provi…
for
(reco…
of)
loan 2,368 -240 103,327 -640
losses
and
other
reser…
Other
adjus…
relat…
to 76 218 229 237
uncon…
joint
ventu…
Other 821 547 1,966 -15,535
adjus…
AFFO
attri…
to
Sabra $ 116,608 $ 90,706 $ 316,208 $ 268,060
Health
Care
REIT,
Inc.
Lease
termi…
(inco… — -1,518 2,873 -1,518
expen…
net
Cash
porti…
of
loss — 2,884 — 2,884
on
extin…
of
debt
Other
norma… -9,359 81 -8,430 2,619
items…
Norma…
AFFO
attri…
to
Sabra $ 107,249 $ 92,153 $ 310,651 $ 272,045
Health
Care
REIT,
Inc.
Amoun…
per
dilut…
common
share
attri…
to
Sabra
Health
Care
REIT,
Inc.:
Net $ 0.11 $ 0.09 $ 0.17 $ 0.53
income
FFO $ 0.40 $ 0.33 $ 0.75 $ 1.12
Norma… $ 0.39 $ 0.36 $ 1.15 $ 1.09
FFO
AFFO $ 0.45 $ 0.37 $ 1.22 $ 1.10
Norma… $ 0.41 $ 0.38 $ 1.20 $ 1.12
AFFO
Weigh…
avera…
number
of
common
shares
outst…
dilut…
Net
incom…
FFO 259,82… 243,558… 257,18… 241,593…
and
Norma…
FFO
AFFO
and 260,79… 244,468… 258,31… 242,666…
Norma…
AFFO
(1) Other normalizing items for FFO and AFFO for the three and nine months ended
September 30, 2026 include a $10.2 million deferred rent payment related to a
triple-net lease. Other normalizing items for FFO for the nine months ended
September 30, 2025 include a $17.2 million gain reclassified from other
comprehensive loss related to six previously terminated interest rate swaps as
the related forecasted transactions were determined to be probable not to occur
and $3.4 million of transition expenses related to the transition of SHOP
communities to new operators. Other normalizing items for AFFO for the nine
months ended September 30, 2025 include $3.4 million of transition expenses
related to the transition of SHOP communities to new operators. In addition,
other normalizing items for FFO and AFFO include triple-net operating expenses,
net of recoveries.
(2) Other adjustments for the nine months ended September 30, 2025 include a
$17.2 million gain reclassified from other comprehensive loss related to six
previously terminated interest rate swaps as the related forecasted transactions
were determined to be probable not to occur.
9
REPORTING DEFINITIONS
Adjusted EBITDA*
Adjusted EBITDA is calculated as earnings before interest, taxes, depreciation
and amortization (“EBITDA”) excluding the impact of merger-related costs, stock-
based compensation expense under the Company’s long-term equity award program
and loan loss reserves. Adjusted EBITDA is an important non-GAAP supplemental
measure of operating performance.
Cash Net Operating Income (“Cash NOI”)*
The Company believes that net income as defined by GAAP is the most appropriate
earnings measure. The Company considers Cash NOI an important supplemental
measure because it allows investors, analysts and its management to evaluate the
operating performance of its investments. The Company defines Cash NOI as total
revenues less operating expenses and non-cash revenues and expenses. Cash NOI
excludes all other financial statement amounts included in net income and is
presented at Sabra’s pro rata share.
EBITDARM
Earnings before interest, taxes, depreciation, amortization, rent and management
fees (“EBITDARM”) for a particular facility accruing to the operator/tenant of
the property (not the Company), for the period presented. The Company uses
EBITDARM in determining EBITDARM Coverage. EBITDARM has limitations as an
analytical tool. EBITDARM does not reflect historical cash expenditures or
future cash requirements for facility capital expenditures or contractual
commitments. In addition, EBITDARM does not represent a property’s net income or
cash flows from operations and should not be considered an alternative to those
indicators. The Company utilizes EBITDARM to evaluate the core operations of the
properties by eliminating management fees, which may vary by operator/tenant and
operating structure, and as a supplemental measure of the ability of the
Company’s operators/tenants and relevant guarantors to generate sufficient
liquidity to meet related obligations to the Company.
EBITDARM Coverage
Represents the ratio of EBITDARM to cash rent for owned facilities (excluding
SHOP communities) for the period presented. EBITDARM Coverage is a supplemental
measure of a property’s ability to generate cash flows for the operator/tenant
(not the Company) to meet the operator’s/tenant’s related cash rent and other
obligations to the Company. However, its usefulness is limited by, among other
things, the same factors that limit the usefulness of EBITDARM. EBITDARM
Coverage includes only Stabilized Facilities and excludes facilities for which
data is not available or meaningful.
Funds From Operations (“FFO”) and Adjusted Funds from Operations (“AFFO”)*
The Company believes that net income as defined by GAAP is the most appropriate
earnings measure. The Company also believes that funds from operations, or FFO,
as defined in accordance with the definition used by the National Association of
Real Estate Investment Trusts (“Nareit”), and adjusted funds from operations, or
AFFO (and related per share amounts) are important non-GAAP supplemental
measures of the Company’s operating performance. Because the historical cost
accounting convention used for real estate assets requires straight-line
depreciation (except on land), such accounting presentation implies that the
value of real estate assets diminishes predictably over time. However, since
real estate values have historically risen or fallen with market and other
conditions, presentations of operating results for a real estate investment
trust that uses historical cost accounting for depreciation could be less
informative. Thus, Nareit created FFO as a supplemental measure of operating
performance for real estate investment trusts that excludes historical cost
depreciation and amortization, among other items, from net income, as defined by
GAAP. FFO is defined as net income, computed in accordance with GAAP, excluding
gains or losses from real estate dispositions and the Company’s share of gains
or losses from real estate dispositions related to its unconsolidated joint
ventures, plus real estate depreciation and amortization, net of amounts related
to noncontrolling interests, plus the Company’s share of depreciation and
amortization related to its unconsolidated joint ventures, and real estate
impairment charges of both consolidated and unconsolidated entities when the
impairment is directly attributable to decreases in the value of depreciable
real estate held by the entity. AFFO is defined as FFO excluding stock-based
compensation expense, non-cash rental and related revenues, non-cash interest
income, non-cash interest expense, non-cash portion of loss on extinguishment of
debt, provision for (recovery of) loan losses and other reserves, non-cash lease
termination income and deferred income taxes, as well as other non-cash revenue
and expense items (including noncapitalizable acquisition costs, transaction
costs related to operator transitions and organizational or other restructuring
activities, gain/loss on derivative instruments, and non-cash revenue and
expense amounts related to noncontrolling interests) and the Company’s share of
non-cash adjustments related to its unconsolidated joint ventures. The Company
believes that the use of FFO and AFFO (and the related per share amounts),
combined with the required GAAP presentations, improves the understanding of the
Company’s
10
REPORTING DEFINITIONS
operating results among investors and makes comparisons of operating results
among real estate investment trusts more meaningful. The Company considers FFO
and AFFO to be useful measures for reviewing comparative operating and financial
performance because, by excluding the applicable items listed above, FFO and
AFFO can help investors compare the operating performance of the Company between
periods or as compared to other companies. While FFO and AFFO are relevant and
widely used measures of operating performance of real estate investment trusts,
they do not represent cash flows from operations or net income as defined by
GAAP and should not be considered an alternative to those measures in evaluating
the Company’s liquidity or operating performance. FFO and AFFO also do not
consider the costs associated with capital expenditures related to the Company’s
real estate assets nor do they purport to be indicative of cash available to
fund the Company’s future cash requirements. Further, the Company’s computation
of FFO and AFFO may not be comparable to FFO and AFFO reported by other real
estate investment trusts that do not define FFO in accordance with the current
Nareit definition or that interpret the current Nareit definition or define AFFO
differently than the Company does.
Investment
Represents the carrying amount of real estate assets after adding back
accumulated depreciation and amortization and excludes net intangible assets and
liabilities.
Net Debt*
The principal balances of the Company’s revolving credit facility, term loans,
senior unsecured notes and secured indebtedness as reported in the Company’s
consolidated financial statements, net of cash and cash equivalents as reported
in the Company’s consolidated financial statements.
Net Debt to Adjusted EBITDA*
The Company believes that net income as defined by GAAP is the most appropriate
earnings measure. The Company considers Net Debt to Adjusted EBITDA an important
supplemental measure because it provides investors, analysts and its management
with a meaningful indicator of the Company’s financial leverage and its capacity
to service and repay debt from operating cash flows. Net Debt to Adjusted EBITDA
is calculated as Net Debt divided by Annualized Adjusted EBITDA, which is
Adjusted EBITDA, as adjusted for annualizing adjustments that give effect to the
acquisitions and dispositions completed during the respective period as though
such acquisitions and dispositions were completed as of the beginning of the
period presented.
Net Operating Income (“NOI”)*
The Company believes that net income as defined by GAAP is the most appropriate
earnings measure. The Company considers NOI an important supplemental measure
because it allows investors, analysts and its management to evaluate the
operating performance of its investments. The Company defines NOI as total
revenues less operating expenses. NOI excludes all other financial statement
amounts included in net income.
Normalized FFO and Normalized AFFO*
Normalized FFO and Normalized AFFO represent FFO and AFFO, respectively,
adjusted for certain income and expense items that the Company does not believe
are indicative of its ongoing operating results. The Company considers
Normalized FFO and Normalized AFFO to be useful measures to evaluate the
Company’s operating results excluding these income and expense items to help
investors compare the operating performance of the Company between periods or as
compared to other companies. Normalized FFO and Normalized AFFO do not represent
cash flows from operations or net income as defined by GAAP and should not be
considered an alternative to those measures in evaluating the Company’s
liquidity or operating performance. Normalized FFO and Normalized AFFO also do
not consider the costs associated with capital expenditures related to the
Company’s real estate assets nor do they purport to be indicative of cash
available to fund the Company’s future cash requirements. Further, the Company’s
computation of Normalized FFO and Normalized AFFO may not be comparable to
Normalized FFO and Normalized AFFO reported by other real estate investment
trusts that do not define FFO in accordance with the current Nareit definition
or that interpret the current Nareit definition or define FFO and AFFO or
Normalized FFO and Normalized AFFO differently than the Company does.
Senior Housing
Senior Housing communities include independent living, assisted living,
continuing care retirement and memory care communities.
11
REPORTING DEFINITIONS
Senior Housing Operating Portfolio (“SHOP”)
Senior Housing communities operated by third-party property managers pursuant to
property management agreements.
Skilled Nursing/Transitional Care
Skilled Nursing/Transitional Care facilities include skilled nursing,
transitional care and multi-license designation facilities.
Specialty Hospitals and Other
Includes psychiatric, acute care, long-term acute care and rehabilitation
hospitals, facilities that provide residential services, which may include
assistance with activities of daily living, and other facilities not classified
as Skilled Nursing/Transitional Care or Senior Housing.
Stabilized Facility
At the time of acquisition, the Company classifies each facility as either
stabilized or non-stabilized. In addition, the Company may classify a facility
as non-stabilized after acquisition. Circumstances that could result in a
facility being classified as non-stabilized include newly completed
developments, facilities undergoing major renovations or additions, facilities
being repositioned or transitioned to new operators and significant transitions
within the tenants’ business model. Such facilities are typically reclassified
to stabilized upon the earlier of maintaining consistent performance or 24
months after the date of classification as non-stabilized. Stabilized Facilities
generally exclude (i) facilities held for sale, (ii) strategic disposition
candidates, (iii) facilities being transitioned to a new operator, (iv)
facilities being transitioned from being leased by the Company to being operated
by the Company and (v) leased facilities acquired during the three months
preceding the period presented.
*Non-GAAP Financial Measures
Reconciliations, definitions and important discussions regarding the usefulness
and limitations of the Non-GAAP Financial Measures used in this supplement can
be found at https://ir.sabrahealth.com/investors/financials/quarterly-results.
12